Researchers from Tr1x Inc. presented the development of TRX-319, a novel allogeneic regulatory T-cell therapy designed for the treatment of autoimmune disorders.
13don MSN
Gut 'primes' pathogenic T cells responsible for neuroinflammation in multiple sclerosis, study finds
Multiple sclerosis (MS) is a debilitating neurological disorder caused by malfunctioning immune responses that target the ...
Autoimmune diseases share the same core pathology despite their differing clinical manifestations: dysregulated B and T cell activity. B cells contribute to disease progression by secreting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results